This new AML trial for those who've failed other drugs (like venetoclax) is genuinely hopeful. 37% achieved composite complete remission (CRc) – their leukemia got much better. That's like going from 1 out of 8 patients to almost 3 out of 8! Early, but promising.
Moleculin's MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetolax-FaMoleculin Biotech announced updated preliminary blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin in combination with cytarabine for treating relapsed or refractory acutmoleculin.com